1. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV–Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial
- Author
-
Wang, Ran, Sun, Lijun, Wang, Xi, Zhai, Yuanyi, Wang, Lijing, Ma, Ping, Wu, Cuisong, Zhou, Yingquan, Chen, Renfang, Wang, Rugang, Zhang, Fengchi, Hua, Wei, Li, Aixin, Xia, Wei, Gao, Yue, Li, Rui, Lv, Shiyun, Shao, Ying, Cao, Yu, and Zhang, Tong
- Subjects
COMBINATION drug therapy ,MEN ,PATIENT compliance ,ANTIRETROVIRAL agents ,HIV seroconversion ,VIRAL load ,DRUG side effects ,PATIENT safety ,BODY mass index ,RESEARCH funding ,TENOFOVIR ,STATISTICAL sampling ,CD4 lymphocyte count ,FISHER exact test ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,MANN Whitney U Test ,CHI-squared test ,HIGHLY active antiretroviral therapy ,EMTRICITABINE ,ANTIVIRAL agents ,RNA ,HOMOSEXUALITY ,DRUG efficacy ,RESEARCH ,DRUGS ,CONFIDENCE intervals ,DATA analysis software ,TIME ,EVALUATION - Abstract
Background Most international treatment guidelines recommend rapid initiation of antiretroviral therapy (ART) for people newly diagnosed with human immunodeficiency virus (HIV)-1 infection, but experiences with rapid ART initiation remain limited in China. We aimed to evaluate the efficacy and safety of efavirenz (400 mg) plus lamivudine and tenofovir disoproxil fumarate (EFV + 3TC + TDF) versus coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in rapid ART initiation among men who have sex with men (MSM) who have been diagnosed with HIV. Methods This multicenter, open-label, randomized clinical trial enrolled MSM aged ≥18 years to start ART within 14 days of confirmed HIV diagnosis. The participants were randomly assigned in a 1:1 ratio to receive EFV (400 mg) + 3TC + TDF or BIC/FTC/TAF. The primary end point was viral suppression (<50 copies/mL) at 48 weeks per US Food and Drug Administration Snapshot analysis. Results Between March 2021 and July 2022, 300 participants were enrolled; 154 were assigned to receive EFV + 3TC + TDF (EFV group) and 146 BIC/FTC/TAF (BIC group). At week 48, 118 (79.2%) and 140 (95.9%) participants in the EFV and BIC group, respectively, were retained in care with viral suppression, and 24 (16.1%) and 1 (0.7%) participant in the EFV and BIC group (P <.001), respectively, discontinued treatment because of adverse effects, death, or lost to follow-up. The median increase of CD4 count was 181 and 223 cells/μL (P =.020), respectively, for the EFV and BIC group, at week 48. The overall incidence of adverse effects was significantly higher for the EFV group (65.8% vs 37.7%, P <.001). Conclusions BIC/FTC/TAF was more efficacious and safer than EFV (400 mg) + 3TC + TDF for rapid ART initiation among HIV-positive MSM in China. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF